Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20876287 | 0.83 | NEU3 (0.36) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19437420 | 0.81 | KMT2A (0.41) | KMT2AMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL20876256 | 0.80 | MEN1 (0.41) | KMT2AMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL20887369 | 0.77 | BRD4 (0.45) | — | |
| SCHEMBL19437415 | 0.75 | CA12 (0.43) | KMT2AMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL24592976 | 0.74 | PTPN1 (0.32) | — | |
| SCHEMBL20887348 | 0.73 | POLQ (0.38) | KMT2AMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL29730828 | 0.72 | CA12 (0.51) | KMT2AMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL3511226 | 0.71 | CA12 (0.58) | KMT2AMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL19456247 | 0.71 | MAPT (0.39) | KMT2AMAPTTP53MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3692026-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068783-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRPF3 | KMT2A 485/4885MAPT 982/4885TP53 1456/4885 |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | BRD4, BRD3, BRPF3 | KMT2A 485/4885MAPT 982/4885TP53 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.